Tenpoint Therapeutics
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases. The company is addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision.
Sector
Biopharmaceuticals
Strategy
Capital
Website
www.tenpointtherapeutics.com
Related News
Tenpoint Therapeutics announces positive topline data from Phase 3 pivotal study, BRIO-II, of BRIMOCHOL™ PF for the treatment of presbyopia
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines
Tenpoint Therapeutics launches with $70 million Series A financing to reverse vision loss through engineered cell-based therapeutics and in vivo reprogramming
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.